REG - IXICO plc - Result of AGM

IXICOAnnouncement

20/01/2022 10:55

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220120:nRST1112Za&default-theme=true

RNS Number : 1112Z  IXICO plc  20 January 2022

 

20 January 2022

IXICO plc

("IXICO" or the "Company")

 

Results of AGM

 

IXICO plc (AIM: IXI), the AI digital technologies company serving
neuroscience, announces that all resolutions put forward to its Annual General
Meeting held earlier today were duly passed and the votes cast were as
follows:

 

 

     RESOLUTION                         VOTES       %      VOTES     %     VOTES       % ISC VOTED  VOTES

FOR
AGAINST
TOTAL
WITHHELD
 1   Reports and Accounts               30,181,599  99.99  800       0.01  30,184,099  62.69        1,700

 2a  Re-election of Charles Spicer      30,166,631  99.97  10,107    0.03  30,184,099  62.69        7,361

 2b  Re-election of Grant Nash          30,166,931  99.97  9,807     0.03  30,184,099  62.69        7,361
 3   Re-appointment of Auditors         29,764,948  98.66  405,081   1.34  30,184,099  62.69        14,070

 4   Allotment of Securities            30,172,562  99.97  10,037    0.03  30,184,099  62.69        1,500

 5   * Disapply Pre-Emption Provisions  30,149,112  99.89  33,487    0.11  30,184,099  62.69        1,500

* Special Resolution

Please note that a 'vote withheld' is not a vote under English Law and is not
counted in the calculation of the proportion of the votes 'for' and 'against'
a resolution.

 

For further information please contact:

 

 IXICO plc                                                    +44 (0)20 3763 7498
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                       +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson (Sales)

 Walbrook PR Ltd      +44 (0)20 7933 8780
 Paul McManus / Lianne Applegarth /        IXICO@walbrookpr.com (mailto:IXICO@walbrookpr.com)
 Alice Woodings

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to
advance medicine and human health by turning data into clinically meaningful
information, providing valuable new insights in neuroscience and our goal is
to be a leading proponent of artificial intelligence in medical image
analysis. We will achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform, to improve
the return on investment in drug development and reduce risk and uncertainty
in clinical trials for our pharmaceutical clients.

More information is available on www.IXICO.com (http://www.ixico.com/)  and
follow us on Twitter @IxicOplc

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGBKKBQKBKDADB